Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/46219
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorELHASSAN, Y. S.-
dc.contributor.authorALTIERI, B.-
dc.contributor.authorBERHANE, S.-
dc.contributor.authorCOSENTINI, D.-
dc.contributor.authorCALABRESE, A.-
dc.contributor.authorHAISSAGUERRE, M.-
dc.contributor.authorKASTELAN, D.-
dc.contributor.authorV, M. C. B. Fragoso-
dc.contributor.authorBERTHERAT, J.-
dc.contributor.authorGHUZLAN, A. Al-
dc.contributor.authorHAAK, H.-
dc.contributor.authorBOUDINA, M.-
dc.contributor.authorCANU, L.-
dc.contributor.authorLOLI, P.-
dc.contributor.authorSHERLOCK, M.-
dc.contributor.authorKIMPEL, O.-
dc.contributor.authorLAGANA, M.-
dc.contributor.authorSITCH, A. J.-
dc.contributor.authorKROISS, M.-
dc.contributor.authorARLT, W.-
dc.contributor.authorTERZOLO, M.-
dc.contributor.authorBERRUTI, A.-
dc.contributor.authorDEEKS, J. J.-
dc.contributor.authorLIBE, R.-
dc.contributor.authorFASSNACHT, M.-
dc.contributor.authorRONCHI, C. L.-
dc.date.accessioned2022-04-19T13:07:10Z-
dc.date.available2022-04-19T13:07:10Z-
dc.date.issued2022-
dc.identifier.citationEUROPEAN JOURNAL OF ENDOCRINOLOGY, v.186, n.1, p.25-36, 2022-
dc.identifier.issn0804-4643-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/46219-
dc.description.abstractObjective Adrenocortical carcinoma (ACC) has an aggressive but variable clinical course. Prognostic stratification based on the European Network for the Study of Adrenal Tumours stage and Ki67 index is limited. We aimed to demonstrate the prognostic role of a points-based score (S-GRAS) in a large cohort of patients with ACC. Design This is a multicentre, retrospective study on ACC patients who underwent adrenalectomy. Methods The S-GRAS score was calculated as a sum of the following points: tumour stage (1-2 = 0; 3 = 1; 4 = 2), grade (Ki67 index 0-9% = 0; 10-19% = 1; >= 20% = 2 points), resection status (R0 = 0; RX = 1; R1 = 2; R2 = 3), age (<50 years = 0; >= 50 years = 1), symptoms (no = 0; yes = 1), and categorised, generating four groups (0-1, 2-3, 4-5, and 6-9). Endpoints were progression-free survival (PFS) and disease-specific survival (DSS). The discriminative performance of S-GRAS and its components was tested by Harrell's Concordance index (C-index) and Royston-Sauerbrei's R-D(2) statistic. Results We included 942 ACC patients. The S-GRAS score showed superior prognostic performance for both PFS and DSS, with best discrimination obtained using the individual scores (0-9) (C-index = 0.73, R-D(2) = 0.30, and C-index = 0.79, R-D(2) = 0.45, respectively, all P < 0.01vs each component). The superiority of S-GRAS score remained when comparing patients treated or not with adjuvant mitotane (n = 481 vs 314). In particular, the risk of recurrence was significantly reduced as a result of adjuvant mitotane only in patients with S-GRAS 4-5. Conclusion The prognostic performance of S-GRAS is superior to tumour stage and Ki67 in operated ACC patients, independently from adjuvant mitotane. S-GRAS score provides a new important guide for personalised management of ACC (i.e. radiological surveillance and adjuvant treatment).eng
dc.description.sponsorshipDeutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [314061271 TRR 205, FA-466/8-1, RO-5435/3-1, FA-466/4-2]-
dc.description.sponsorshipDeutsche KrebshilfeDeutsche Krebshilfe [70113526]-
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2017/26345-5]-
dc.description.sponsorshipNIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust-
dc.description.sponsorshipUniversity of Birmingham-
dc.language.isoeng-
dc.publisherBIOSCIENTIFICA LTDeng
dc.relation.ispartofEuropean Journal of Endocrinology-
dc.rightsrestrictedAccesseng
dc.subject.otheradjuvant mitotaneeng
dc.subject.othergenomic characterizationeng
dc.subject.othereuropean networkeng
dc.subject.othersurvivaleng
dc.subject.otherresectioneng
dc.subject.othermanagementeng
dc.subject.otheroutcomeseng
dc.subject.othercancereng
dc.subject.otherrecurrenceeng
dc.subject.othernomogramseng
dc.titleS-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT studyeng
dc.typearticleeng
dc.rights.holderCopyright BIOSCIENTIFICA LTDeng
dc.contributor.groupauthorENSAT-
dc.identifier.doi10.1530/EJE-21-0510-
dc.identifier.pmid34709200-
dc.subject.wosEndocrinology & Metabolismeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalELHASSAN, Y. S.:Univ Birmingham, Inst Metab & Syst Res, Birmingham, W Midlands, England; Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Dept Endocrinol, Birmingham, W Midlands, England-
hcfmusp.author.externalALTIERI, B.:Univ Wurzburg, Univ Hosp, Dept Internal Med 1, Div Endocrinol & Diabet, Wurzburg, Germany-
hcfmusp.author.externalBERHANE, S.:Univ Hosp Birmingham NHS Fdn Trust, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England; Univ Birmingham, Birmingham, W Midlands, England; Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England-
hcfmusp.author.externalCOSENTINI, D.:Radiol Sci & Publ Hlth Univ Brescia, Dept Med & Surg Specialties, Med Oncol, ASST Spedali Civili, Brescia, Italy-
hcfmusp.author.externalCALABRESE, A.:Univ Turin, San Luigi Hosp, Dept Clin & Biol Sci, Orbassano, Italy-
hcfmusp.author.externalHAISSAGUERRE, M.:CHU Bordeaux, Serv Endocrinol Diabet & Nutr, Bordeaux, France-
hcfmusp.author.externalKASTELAN, D.:Univ Hosp Ctr Zagreb, Dept Endocrinol, Zagreb, Croatia-
hcfmusp.author.externalBERTHERAT, J.:Cochin Hosp, Reference Ctr Rare Adrenal Canc COMETE, Paris, France-
hcfmusp.author.externalGHUZLAN, A. Al:Gustave Roussy Canc Ctr, Dept Pathol, Paris, France-
hcfmusp.author.externalHAAK, H.:Maxima MC, Dept Internal Med, Eindhoven, Netherlands-
hcfmusp.author.externalBOUDINA, M.:Theagenio Canc Hosp, Dept Endocrinol, Thessaloniki, Greece-
hcfmusp.author.externalCANU, L.:Univ Florence, Dept Expt & Clin Biomed Sci, Florence, Italy-
hcfmusp.author.externalLOLI, P.:Clin Polispecialist San Carlo, Milan, Italy-
hcfmusp.author.externalSHERLOCK, M.:Beaumont Hosp, Dept Endocrinol, Dublin, Ireland; Royal Coll Surg, Dublin, Ireland-
hcfmusp.author.externalKIMPEL, O.:Univ Wurzburg, Univ Hosp, Dept Internal Med 1, Div Endocrinol & Diabet, Wurzburg, Germany-
hcfmusp.author.externalLAGANA, M.:Radiol Sci & Publ Hlth Univ Brescia, Dept Med & Surg Specialties, Med Oncol, ASST Spedali Civili, Brescia, Italy-
hcfmusp.author.externalSITCH, A. J.:Univ Hosp Birmingham NHS Fdn Trust, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England; Univ Birmingham, Birmingham, W Midlands, England; Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England-
hcfmusp.author.externalKROISS, M.:Univ Wurzburg, Univ Hosp, Dept Internal Med 1, Div Endocrinol & Diabet, Wurzburg, Germany; Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; Ludwig Maximilians Univ Munchen, Dept Endocrinol, Med Klin & Poliklin 4, Munich, Germany-
hcfmusp.author.externalARLT, W.:Univ Birmingham, Inst Metab & Syst Res, Birmingham, W Midlands, England; Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Dept Endocrinol, Birmingham, W Midlands, England; Univ Hosp Birmingham NHS Fdn Trust, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England; Univ Birmingham, Birmingham, W Midlands, England-
hcfmusp.author.externalTERZOLO, M.:Univ Turin, San Luigi Hosp, Dept Clin & Biol Sci, Orbassano, Italy-
hcfmusp.author.externalBERRUTI, A.:Radiol Sci & Publ Hlth Univ Brescia, Dept Med & Surg Specialties, Med Oncol, ASST Spedali Civili, Brescia, Italy-
hcfmusp.author.externalDEEKS, J. J.:Univ Hosp Birmingham NHS Fdn Trust, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England; Univ Birmingham, Birmingham, W Midlands, England; Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England-
hcfmusp.author.externalLIBE, R.:Hop Cochin, Dept Endocrinol & Metab Dis, Paris, France-
hcfmusp.author.externalFASSNACHT, M.:Univ Wurzburg, Univ Hosp, Dept Internal Med 1, Div Endocrinol & Diabet, Wurzburg, Germany; Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany-
hcfmusp.author.externalRONCHI, C. L.:Univ Birmingham, Inst Metab & Syst Res, Birmingham, W Midlands, England; Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Dept Endocrinol, Birmingham, W Midlands, England; Univ Wurzburg, Univ Hosp, Dept Internal Med 1, Div Endocrinol & Diabet, Wurzburg, Germany-
hcfmusp.description.beginpage25-
hcfmusp.description.endpage36-
hcfmusp.description.issue1-
hcfmusp.description.volume186-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000750751100009-
hcfmusp.origem.id2-s2.0-85122438557-
hcfmusp.publisher.cityBRISTOLeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceAbiven G, 2006, J CLIN ENDOCR METAB, V91, P2650, DOI 10.1210/jc.2005-2730eng
hcfmusp.relation.referenceAssie G, 2007, J CLIN ENDOCR METAB, V92, P148, DOI 10.1210/jc.2006-0706eng
hcfmusp.relation.referenceAssie G, 2014, NAT GENET, V46, P607, DOI 10.1038/ng.2953eng
hcfmusp.relation.referenceBaechle JJ, 2021, ANN SURG ONCOL, V28, P6551, DOI 10.1245/s10434-020-09562-8eng
hcfmusp.relation.referenceBedrose S, 2020, CANCERS, V12, DOI 10.3390/cancers12020508eng
hcfmusp.relation.referenceBerruti A, 2017, J CLIN ENDOCR METAB, V102, P1358, DOI 10.1210/jc.2016-2894eng
hcfmusp.relation.referenceBerruti A, 2014, EUR UROL, V65, P832, DOI 10.1016/j.eururo.2013.11.006eng
hcfmusp.relation.referenceBeuschlein F, 2015, J CLIN ENDOCR METAB, V100, P841, DOI 10.1210/jc.2014-3182eng
hcfmusp.relation.referenceCalabrese A, 2019, EUR J ENDOCRINOL, V180, P387, DOI 10.1530/EJE-18-0923eng
hcfmusp.relation.referencede Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678eng
hcfmusp.relation.referenceElse T, 2014, ENDOCR REV, V35, P282, DOI 10.1210/er.2013-1029eng
hcfmusp.relation.referenceElse T, 2014, J CLIN ENDOCR METAB, V99, P455, DOI 10.1210/jc.2013-2856eng
hcfmusp.relation.referenceErdogan I, 2013, J CLIN ENDOCR METAB, V98, P181, DOI 10.1210/jc.2012-2559eng
hcfmusp.relation.referenceEttaieb MHT, 2020, CANCERS, V12, DOI 10.3390/cancers12092720eng
hcfmusp.relation.referenceFassnacht M, 2020, ANN ONCOL, V31, P1476, DOI 10.1016/j.annonc.2020.08.2099eng
hcfmusp.relation.referenceFassnacht M, 2018, EUR J ENDOCRINOL, V179, pG1, DOI 10.1530/EJE-18-0608eng
hcfmusp.relation.referenceFassnacht M, 2010, J CLIN ENDOCR METAB, V95, P4925, DOI 10.1210/jc.2010-0803eng
hcfmusp.relation.referenceFassnacht M, 2009, CANCER-AM CANCER SOC, V115, P243, DOI 10.1002/cncr.24030eng
hcfmusp.relation.referenceGrubbs EG, 2010, ANN SURG ONCOL, V17, P263, DOI 10.1245/s10434-009-0716-xeng
hcfmusp.relation.referenceHARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543eng
hcfmusp.relation.referenceJinks RC, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0078-yeng
hcfmusp.relation.referenceJohanssen S, 2010, DTSCH ARZTEBL INT, V107, P885, DOI 10.3238/arztebl.2010.0885eng
hcfmusp.relation.referenceJouinot A, 2017, J CLIN ENDOCR METAB, V102, P923, DOI 10.1210/jc.2016-3205eng
hcfmusp.relation.referenceKebebew E, 2006, WORLD J SURG, V30, P872, DOI 10.1007/s00268-005-0329-xeng
hcfmusp.relation.referenceKerkhofs TMA, 2013, EUR J CANCER, V49, P2579, DOI 10.1016/j.ejca.2013.02.034eng
hcfmusp.relation.referenceKim Y, 2016, JAMA SURG, V151, P365, DOI 10.1001/jamasurg.2015.4516eng
hcfmusp.relation.referenceKimpel O, 2021, BRIT J CANCER, V125, P1233, DOI 10.1038/s41416-021-01513-8eng
hcfmusp.relation.referenceKong JQ, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0426-0eng
hcfmusp.relation.referenceLi Y, 2018, CANCER MANAG RES, V10, P6949, DOI 10.2147/CMAR.S187169eng
hcfmusp.relation.referenceLiang JY, 2020, ENDOCRINE, V67, P449, DOI 10.1007/s12020-019-02141-2eng
hcfmusp.relation.referenceLibe R, 2015, ANN ONCOL, V26, P2119, DOI 10.1093/annonc/mdv329eng
hcfmusp.relation.referenceLippert J, 2018, J CLIN ENDOCR METAB, V103, P4511, DOI 10.1210/jc.2018-01348eng
hcfmusp.relation.referenceLughezzani G, 2010, EUR J CANCER, V46, P713, DOI 10.1016/j.ejca.2009.12.007eng
hcfmusp.relation.referenceMargonis GA, 2016, AM J SURG, V211, P1106, DOI 10.1016/j.amjsurg.2015.09.020eng
hcfmusp.relation.referenceNewson RB, 2010, STATA J, V10, P339, DOI 10.1177/1536867X1001000303eng
hcfmusp.relation.referencePostlewait LM, 2016, J AM COLL SURGEONS, V222, P480, DOI 10.1016/j.jamcollsurg.2015.12.013eng
hcfmusp.relation.referenceTerzolo M, 2007, NEW ENGL J MED, V356, P2372, DOI 10.1056/NEJMoa063360eng
hcfmusp.relation.referenceVanbrabant T, 2018, EUR J ENDOCRINOL, V179, P429, DOI 10.1530/EJE-18-0450eng
hcfmusp.relation.referenceZheng SY, 2016, CANCER CELL, V29, P723, DOI 10.1016/j.ccell.2016.04.002eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1479-683X-
hcfmusp.citation.scopus7-
hcfmusp.scopus.lastupdate2022-09-15-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/42
LIM/42 - Laboratório de Hormônios e Genética Molecular


Files in This Item:
File Description SizeFormat 
art_ELHASSAN_SGRAS_score_for_prognostic_classification_of_adrenocortical_carcinoma_2022.PDF
  Restricted Access
publishedVersion (English)2.73 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.